Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh C. Buyukkaramikli; Hedwig M. Blommestein; Rob Riemsma; Nigel Armstrong; Fiona J. Clay; Janine Ross; Gill Worthy; Johan Severens; Jos Kleijnen; Maiwenn J. Al

doi:10.1007/s40273-017-0528-y

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh C. Buyukkaramikli^*, Hedwig M. Blommestein, Rob Riemsma, Nigel Armstrong, Fiona J. Clay, Janine Ross, Gill Worthy, Johan Severens, Jos Kleijnen, Maiwenn J. Al

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Pages (from-to)	1211-1221
Number of pages	11
Journal	Pharmacoeconomics
Volume	35
Issue number	12
DOIs	https://doi.org/10.1007/s40273-017-0528-y
Publication status	Published - Dec 2017

Keywords

HEALTH STATE UTILITIES
RANDOMIZED PHASE-III
SUPPORTIVE CARE
OPEN-LABEL
TRIAL
IRINOTECAN
PLUS
COMBINATION
MONOTHERAPY
PACLITAXEL

Access to Document

10.1007/s40273-017-0528-y

Cite this

Buyukkaramikli, N. C., Blommestein, H. M., Riemsma, R., Armstrong, N., Clay, F. J., Ross, J., Worthy, G., Severens, J., Kleijnen, J., & Al, M. J. (2017). Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 35(12), 1211-1221. https://doi.org/10.1007/s40273-017-0528-y

Buyukkaramikli, Nasuh C. ; Blommestein, Hedwig M. ; Riemsma, Rob ; Armstrong, Nigel ; Clay, Fiona J. ; Ross, Janine ; Worthy, Gill ; Severens, Johan ; Kleijnen, Jos ; Al, Maiwenn J. / Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2017 ; Vol. 35, No. 12. pp. 1211-1221.

@article{644e60278d434ea883f4d60b589f5124,

title = "Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

keywords = "HEALTH STATE UTILITIES, RANDOMIZED PHASE-III, SUPPORTIVE CARE, OPEN-LABEL, TRIAL, IRINOTECAN, PLUS, COMBINATION, MONOTHERAPY, PACLITAXEL",

author = "Buyukkaramikli, {Nasuh C.} and Blommestein, {Hedwig M.} and Rob Riemsma and Nigel Armstrong and Clay, {Fiona J.} and Janine Ross and Gill Worthy and Johan Severens and Jos Kleijnen and Al, {Maiwenn J.}",

year = "2017",

month = dec,

doi = "10.1007/s40273-017-0528-y",

language = "English",

volume = "35",

pages = "1211--1221",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "12",

}

Buyukkaramikli, NC, Blommestein, HM, Riemsma, R, Armstrong, N, Clay, FJ, Ross, J, Worthy, G, Severens, J, Kleijnen, J & Al, MJ 2017, 'Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 35, no. 12, pp. 1211-1221. https://doi.org/10.1007/s40273-017-0528-y

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Buyukkaramikli, Nasuh C.; Blommestein, Hedwig M.; Riemsma, Rob; Armstrong, Nigel; Clay, Fiona J.; Ross, Janine; Worthy, Gill; Severens, Johan; Kleijnen, Jos; Al, Maiwenn J.

In: Pharmacoeconomics, Vol. 35, No. 12, 12.2017, p. 1211-1221.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Buyukkaramikli, Nasuh C.

AU - Blommestein, Hedwig M.

AU - Riemsma, Rob

AU - Armstrong, Nigel

AU - Clay, Fiona J.

AU - Ross, Janine

AU - Worthy, Gill

AU - Severens, Johan

AU - Kleijnen, Jos

AU - Al, Maiwenn J.

PY - 2017/12

Y1 - 2017/12

KW - HEALTH STATE UTILITIES

KW - RANDOMIZED PHASE-III

KW - SUPPORTIVE CARE

KW - OPEN-LABEL

KW - TRIAL

KW - IRINOTECAN

KW - PLUS

KW - COMBINATION

KW - MONOTHERAPY

KW - PACLITAXEL

U2 - 10.1007/s40273-017-0528-y

DO - 10.1007/s40273-017-0528-y

M3 - Review article

VL - 35

SP - 1211

EP - 1221

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 12

ER -

Buyukkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J et al. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2017 Dec;35(12):1211-1221. https://doi.org/10.1007/s40273-017-0528-y